In total , @ patients were randomized ; @ ( @ in the enoxaparin and @ in the semuloparin groups ) were evaluable for the primary efficacy end point , which occurred in @ patients ( @ % ) in the semuloparin group and @ patients ( @ % ) in the enoxaparin group -LSB- odds ratio ( OR ) = @ , @ % confidence interval ( CI ) : @-@ @ -RSB- .